

Rina Hui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7514355/publications.pdf>

Version: 2024-02-01

66
papers

23,830
citations

201575

27
h-index

138417

58
g-index

66
all docs

66
docs citations

66
times ranked

21973
citing authors

#	ARTICLE	IF	CITATIONS
1	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	0.8	445
2	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. <i>Lung Cancer</i> , 2022, 166, 84-93.	0.9	7
3	Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. , 2022, 10, e003776.		79
4	Abstract OT2-01-03: Trial in progress: Phase 2 study of intratumoral plasmid interleukin-12 (tavokinogene telseplasmid; TAVO ₂) plus electroporation in combination with pembrolizumab with or without chemotherapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (KEYNOTE-890/OMS-1141). <i>Cancer Research</i> , 2022, 82, OT2-01-03-OT2-01-03.	0.4	1
5	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. <i>Cancer Research</i> , 2022, 82, GS1-01-GS1-01.	0.4	5
6	Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. <i>Journal of Clinical Oncology</i> , 2022, 40, 503-503.	0.8	38
7	Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 602-602.	0.8	6
8	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021, 21, 80-91.e7.	1.1	140
9	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). <i>Lung Cancer</i> , 2021, 151, 30-38.	0.9	30
10	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. <i>JNCI Cancer Spectrum</i> , 2021, 5, p _{kab} 012.	1.4	16
11	CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 3-14.	0.7	11
12	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. <i>Future Oncology</i> , 2021, 17, 1165-1184.	1.1	2
13	Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2021, 155, 28-33.	0.9	18
14	Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?. , 2021, 9, e002248.		35
15	Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). <i>Clinical Lung Cancer</i> , 2021, 22, 549-561.	1.1	25
16	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%. <i>Journal of Clinical Oncology</i> , 2021, 39, 2339-2349.	0.8	468
17	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100205.	0.6	32
18	364 KRAS mutations in patients with nonsquamous non-small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status. , 2021, 9, A391-A391.		0

#	ARTICLE	IF	CITATIONS
19	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC Update from PACIFIC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 288-293.	0.5	328
20	Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio. <i>Breast</i> , 2020, 54, 229-234.	0.9	3
21	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1505-1517.	0.8	710
22	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 387-397.	5.1	119
23	Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020, 26, 354-363.	3.2	40
24	Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC). <i>Journal of Clinical Oncology</i> , 2020, 38, 9048-9048.	0.8	1
25	Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC. <i>Journal of Clinical Oncology</i> , 2020, 38, 9521-9521.	0.8	17
26	Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2020, 38, 9582-9582.	0.8	16
27	LAG525 in combination with spartalizumab in patients with advanced malignancies. , 2020, , .		4
28	Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 657-665.	1.0	1
29	Physical Activity for Symptom Management in Women With Metastatic Breast Cancer: A Randomized Feasibility Trial on Physical Activity and Breast Metastases. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 929-939.	0.6	35
30	Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1670-1680.	5.1	125
31	Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2527.	0.8	811
32	Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?. <i>Breast</i> , 2019, 46, 52-57.	0.9	9
33	Patterns of care for stage III non-small cell lung cancer in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 93-100.	0.7	5
34	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 347-357.	5.2	137
35	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. <i>Journal of Clinical Oncology</i> , 2019, 37, 537-546.	0.8	1,144
36	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 371-382.	5.1	327

#	ARTICLE	IF	CITATIONS
37	Three-year overall survival update from the PACIFIC trial.. Journal of Clinical Oncology, 2019, 37, 8526-8526.	0.8	29
38	KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.. Journal of Clinical Oncology, 2019, 37, 9013-9013.	0.8	42
39	First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.. Journal of Clinical Oncology, 2019, 37, 9054-9054.	0.8	3
40	Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non-“small-cell lung cancer (NSCLC): LEAP-006.. Journal of Clinical Oncology, 2019, 37, TPS9118-TPS9118.	0.8	7
41	Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.. Journal of Clinical Oncology, 2019, 37, LBA9015-LBA9015.	0.8	9
42	Pembrolizumab plus Chemotherapy in Metastatic Non-“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 2078-2092.	13.9	4,701
43	Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone. Australasian Journal of Dermatology, 2018, 59, e219-e220.	0.4	6
44	Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.. Journal of Clinical Oncology, 2018, 36, 3012-3012.	0.8	58
45	Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC.. Journal of Clinical Oncology, 2018, 36, 9021-9021.	0.8	15
46	4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.. Journal of Clinical Oncology, 2018, 36, 9030-9030.	0.8	11
47	ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non-“small cell lung cancer (mNSCLC).. Journal of Clinical Oncology, 2018, 36, TPS9104-TPS9104.	0.8	4
48	Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.. Journal of Clinical Oncology, 2018, 36, 524-524.	0.8	2
49	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncology, The, 2017, 18, 1600-1609.	5.1	282
50	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. Journal of Clinical Oncology, 2017, 35, 1008-1008.	0.8	99
51	Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.. Journal of Clinical Oncology, 2017, 35, 9000-9000.	0.8	43
52	KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.. Journal of Clinical Oncology, 2017, 35, 9011-9011.	0.8	18
53	Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010.. Journal of Clinical Oncology, 2017, 35, 77-77.	0.8	6
54	Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. PLoS ONE, 2017, 12, e0175544.	1.1	64

#	ARTICLE	IF	CITATIONS
55	Pembrolizumab versus Chemotherapy for PD-L1â€“Positive Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1823-1833.	13.9	7,847
56	Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoringâ€“The TADE Study. <i>Clinical Cancer Research</i> , 2016, 22, 3164-3171.	3.2	60
57	Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2â€“) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 568-568.	0.8	25
58	Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9026-9026.	0.8	31
59	Pembrolizumab for the Treatment of Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2018-2028.	13.9	5,183
60	Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1â€“positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8026-8026.	0.8	12
61	Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8007-8007.	0.8	32
62	Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8020-8020.	0.8	25
63	Should culture affect practice? Prognostic discussions with immigrants.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6556-6556.	0.8	0
64	Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 543-543.	0.8	26
65	Physical activity and fitness in women with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 136-136.	0.8	0
66	<i>CYP2D6</i> genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.. <i>Journal of Clinical Oncology</i> , 2012, 30, 550-550.	0.8	0